Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

On September 19, 2023 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, reported two poster presentations at the upcoming 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held on October 11-15, 2023, in Boston, MA (Press release, Aprea, SEP 19, 2023, View Source [SID1234635235]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aprea is in development with two assets. Its lead program is ATRN-119, a clinical-stage small-molecule ATR inhibitor being developed for solid tumor indications. It is currently in an ongoing Phase 1/2a trial; details for which can be found here: View Source The company’s second asset, ATRN-1051, is an oral, small-molecule WEE1 inhibitor; Aprea anticipates filing an IND submission in the fourth quarter of 2023.

Details of the poster presentations are as follows:

Poster #1
Title: First in Human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors
Abstract #: C034
Session: Session C; Level 2, Exhibit Hall D
Date/Time: Saturday, October 14 | 12:30pm – 4:00 pm ET
Presenter: Nadeem Q Mirza, M.D., M.P.H., Aprea Therapeutics, Inc.

Poster #2
Title: The DNA replication checkpoint inhibitors, ATRN-1051 (WEE1i) and ATRN-119 (ATRi), are potentially well-tolerated and effective cancer treatments
Abstract #: C147
Session: Session C; Level 2, Exhibit Hall D
Date/Time: Saturday, October 14 | 12:30pm – 4:00 pm ET
Presenter: Eric J. Brown, Ph.D., Perelman School of Medicine, University of Pennsylvania

In addition to the two poster presenters, Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, will be in attendance at the poster sessions and conference.